Crohn's Disease

REFERENCES

• Arber N, Odes HS, Fireman Z et al. A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission. J Clin Gastroenterol 1995; 20: 203–206.
   PubMedGoogle Scholar
• Belluzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil prepara-tion on relapses in Crohn's disease. N Engl J Med 1996; 334: 1557–1560.
   PubMedGoogle Scholar
• Gendre J-P, Mary J-Y, Florent C et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: A multicenter placebo-controlled study. Gastroenterol-ogy 1993; 104: 435–439.
   PubMed Web of Science ®Google Scholar
• Greenberg GR, Feagan BG, Martin F et al. Oral budesonide for active Crohn's diseae. N Engl J Med 1994; 331: 836–841.
   PubMed Web of Science ®Google Scholar
• Greenberg GR, Feagan BG, Martin F et al. Oral budesonide as maintenance treatment for Crohn's disease: A placebo-controlled, dose-ranging study. Gastroenterology 1996; 110: 45–51.
   PubMed Web of Science ®Google Scholar
• Gump FE, Lepore M, Barker HG. A revised concept of acute regional enteritis. Ann Surg 1967; 166: 942–946.
   Google Scholar
• Hetiers G. Crohn's disese in Stockholm county 1955–1974. A study of epidemiology, results of surgical treatment and long-term prognosis. Acta Chir Scand 1979; (suppl 490): 16–30.
   Google Scholar
• Krause U, Bergman L, Norlen BJ. Crohn's disease. A clinical study based on 186 patients. Scand J Gastro-enterol 1971; 6: 97–108.
   Google Scholar
• Kyle J Crohn's disease. London: Heinemann Medical, 1972.
   Google Scholar
• Lindberg E, Järnerot G. The incidence of Crohn's disease is not decreasing in Sweden. Scand J Gastro-enterol 1991; 26: 495–500.
   PubMed Web of Science ®Google Scholar
• Löfberg R, Rutgeerts P. Malchow H et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo-controlled one year study. Gut 1996; 39: 82–86.
   Google Scholar
• Malchow H, Ewe K, Brandes JW et al. European Cooperative Crohn's Disease Study (ECCDS): Results of drug treatment. Gastroenterology 1984; 86: 249–266.
   PubMed Web of Science ®Google Scholar
• Milner JM, Keller HVV, Erasmi H, Picklmaier. Total parenteral nutrition as the sole therapy in Crohn's disease-a prospective study. Br J Surg 1983; 70: 40–43.
   Google Scholar
• Prantera C, Pallone F, Brunetti G et al. Oral 5-aminosalicylic acid (Asacol) in the maintenance treat-ment of Crohn's disease. The Italian IBD study group. Gastroenterology 1992; 103: 363–368.
   Google Scholar
• Rankin GB, Watts HD, Melnyk CS, Kelley Jr ML. National Cooperative Crohn's Disease Study: Extra-intestinal manifestations and perianal compolications. Gastroenterology 1979; 77: 914–920.
   Google Scholar
• Rasmussen SN, Lauritsen K, Tage-Jensen U et al. 5-aminosalicylic acid in the treatment of Crohn's disease. A 16 week double-blind, placebo-controlled, multicentre study with Pentasa®. Scand J Gastroenterol 1987; 22: 877–883.
   PubMed Web of Science ®Google Scholar
• Riordan AM, Hunter JO, Cowan RE et al. Treatment of active Crohn's disease by exclusion diet: East Anglian Multicentre controlled trial. Lancet 1993; 342: 1131–1134.
   PubMed Web of Science ®Google Scholar
• Singleton JW, Hanauer SB, Gitnick GL et al. Mesala-mine capsules for the treatment of active Crohn's disease. Results of a 16 week trial. Gastroenterology 1993; 104: 1293–1301.
   PubMed Web of Science ®Google Scholar
• Smedh K Intraoperative endoscopy and endoscopic surveillance after surgery in Crohn's disease. Linkoping University: Linkoping University Medical Dissertations No 417,1994.
   Google Scholar
• Summers RW, Switz DM, Sessions Jr JT et al. National Co-operative Crohn's Disease Study: Results of drug treatment. Gastroenterology 1979; 77: 847–869.
   Google Scholar
• Sutherland L, Singleton J, Sessions J et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1992; 32: 1071–1075.
   Google Scholar
• Wright JP, Jewell DP, Modigliani R, Malchow H. A randomized, double-blind, placebo-controlled trial of olsalazine for active Crohn's disease. Inflammatory Bowel Diseases 1995; 1: 241–246.
   Google Scholar